Compare · Head-to-head
Melanotan II vs PT-141.
Evidence, risk, regulatory flags, cost, and vendor coverage compared side by side. We don’t sell peptides — we help you choose between them.
Which should you research first?
Start with PT-141, then use the table to confirm fit.
PT-141 is the cleaner first read based on the current evidence, risk, and regulatory data stored for this pair. The right answer can still change if your goal, sport testing status, vendor constraints, or monitoring tolerance makes the other option a better fit.
Comparison next step
Personalize this head-to-head.
Take the quiz before converting a comparison into a compound, vendor, or protocol decision.
01· Subject
Melanotan II
Unlicensed broad melanocortin agonist with pigmentation and sexual side-effect profiles. Highest compliance risk.
01 · At a glance
| Decision factor | Melanotan II | PT-141 |
|---|---|---|
| Primary fit | skin & hair and sexual health & libido comparisons | sexual health & libido research where you want a clear starting point |
| Evidence | Tier C | Tier A |
| Risk | high | low |
| Experience level | advanced | advanced |
| Budget tier | budget | premium |
| Administration route | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Melanotan II | PT-141 |
|---|---|---|
| Goal fit | Skin & Hair, Sexual Health & Libido | Sexual Health & Libido |
| What users compare it for | Pigmentation changes (tanning); sexual arousal effects. NOT a controlled therapeutic product. | Improved sexual desire in premenopausal women with acquired generalized HSDD. |
| Onset timeline | Pigmentation changes can occur quickly; adverse events can be acute. | Designed for acute/as-needed effect within an hour; BP effects peak in hours post-dose. |
| Main tradeoff | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Melanotan II | PT-141 |
|---|---|---|
| Adverse effects | FDA cites serious adverse events: melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, priapism. Immunogenicity/impurity concerns. | Nausea, flushing, injection site reactions, headache, vomiting. BP elevation. |
| Contraindications | High risk across the board; unlicensed and unapproved. | Uncontrolled hypertension, known cardiovascular disease. Avoid co-use with oral naltrexone-containing products. |
| Interaction notes | Unknown; risk may increase with UV exposure behaviors and stimulant-like exposures. | Slowed gastric emptying impacts absorption of concomitant oral meds. Clinically meaningful interaction with oral naltrexone. |
| Regulatory status | Not approved | Prescription-approved |
| FDA flag | FDA compounding caution | No current flag noted |
| WADA status | Status unclear | Not listed |
04 · Age & monitoring
| Decision factor | Melanotan II | PT-141 |
|---|---|---|
| Supported age ranges | No age guidance yet | 25-34, 35-44, 45-54, 55-64 |
| Life-stage note | Not yet documented | Adult sexual-health use case with strongest fit before later-life cardiovascular burden becomes a larger concern. |
| Monitoring burden | Not specified | medium |
| Follow-up cadence | Not yet documented | Review tolerance early and reassess if use becomes frequent. |
05 · Cost & sourcing
| Decision factor | Melanotan II | PT-141 |
|---|---|---|
| Typical cycle cost | $80.00 | €27.29 |
| Estimated monthly cost | $53.33 | €27.29 |
| Cost confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Melanotan II | PT-141 |
|---|---|---|
| Tracked vendor listings | 3 listings | 3 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Better as a standalone decision |
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Still deciding
Get a plan tailored to you.
The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.